Down-regulation of traditional oncomiRs in plasma of breast cancer patients.

Autor:	Jurkovicova D; KRD Molecular Technologies Ltd., Bratislava, Slovakia.; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Smolkova B; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Magyerkova M; KRD Molecular Technologies Ltd., Bratislava, Slovakia., Sestakova Z; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Kajabova VH; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Kulcsar L; KRD Molecular Technologies Ltd., Bratislava, Slovakia., Zmetakova I; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Kalinkova L; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Krivulcik T; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Karaba M; Department of Surgical Oncology, National Cancer Institute, Bratislava, Slovakia., Benca J; Department of Surgical Oncology, National Cancer Institute, Bratislava, Slovakia.; Medical Department of St. Elizabeth University, Bratislava, Slovakia., Sedlackova T; Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Minarik G; Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Cierna Z; Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, University Hospital, Bratislava, Slovakia., Danihel L; Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, University Hospital, Bratislava, Slovakia.; Pathological-Anatomical Workplace, Health Care Surveillance Authority, Bratislava, Slovakia., Mego M; 2 Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia., Chovanec M; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Fridrichova I; Department of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Aug 24; Vol. 8 (44), pp. 77369-77384. Date of Electronic Publication: 2017 Aug 24 (Print Publication: 2017).
DOI:	10.18632/oncotarget.20484
Abstrakt:	Deregulated expression of microRNAs has the oncogenic or tumor suppressor function in cancer. Since miRNAs in plasma are highly stable, their quantification could contribute to more precise cancer diagnosis, prognosis and therapy prediction. We have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients. We detected down-regulation of six miRNAs in patients with invasive BC compared to controls; however, only miR-20a and miR-27a down-regulations were statistically significant. Comparing miRNA expression between early and advanced stages of BC, we observed statistically significant decrease of miR-17 and miR-19a. We identified down-regulation of miR-17 and miR-20a in patients with clinical parameters of advanced BC (lymph node metastasis, tumor grade 3, circulating tumor cells, higher Ki-67-related proliferation, hormone receptor negativity and HER2 amplification), when compared to controls. Moreover, decreased level of miR-17 was found from low to high grade. Therefore, miR-17 could represent an indicator of advanced BC. Down-regulated miR-27a expression levels were observed in all clinical categories regardless of tumor progression. Hence, miR-27a could be used as a potential diagnostic marker for BC. Our data indicates that any changes in miRNA expression levels in BC patients in comparison to controls could be highly useful for cancer-associated pathology discrimination. Moreover, dynamics of miRNA expression changes could be used for BC progression monitoring. Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu